Description
Flufenamic acid is a COX-inhibiting non-steroidal anti-inflammatory drug (NSAID) that exhibits neuromodulatory, anti-inflammatory, antipyretic, analgesic, and antiepileptic/anticonvulsant activities. Flufenamic inhibits voltage-gated Na+ channels, transient receptor potential canonical 3 (TRPC3) channels, and transient receptor potential melastatin-like 2 (TRPM2) channels and potentiates TREK1 (KCNK2) channel activity. In vitro, flufenamic acid decreases glutamatergic excitatory activity and neuronal excitability.
References
Xie YF, Zhou F. TRPC3 channel mediates excitation of striatal cholinergic interneurons. Neurol Sci. 2014 May 21. [Epub ahead of print]. PMID: 24844791.
Veale EL, Al-Moubarak E, Bajaria N, et al. Influence of the N terminus on the biophysical properties and pharmacology of TREK1 potassium channels. Mol Pharmacol. 2014 May;85(5):671-81. PMID: 24509840.
Nazıroğlu M, Özgül C, Çelik Ö, et al. Aminoethoxydiphenyl borate and flufenamic acid inhibit Ca2+ influx through TRPM2 channels in rat dorsal root ganglion neurons activated by ADP-ribose and rotenone. J Membr Biol. 2011 May;241(2):69-75. PMID: 21509529.
Yau HJ, Baranauskas G, Martina M. Flufenamic acid decreases neuronal excitability through modulation of voltage-gated sodium channel gating. J Physiol. 2010 Oct 15;588(Pt 20):3869-82. PMID: 20724367.
Fernández M, Lao-Peregrín C, Martín ED. Flufenamic acid suppresses epileptiform activity in hippocampus by reducing excitatory synaptic transmission and neuronal excitability. Epilepsia. 2010 Mar;51(3):384-90. PMID: 19732136.
